La Caisha Foundation awarded three new grants to biomedical innovation projects leadership within the CaixaResearch Consolidate call. The ultimate goal of CaixaResearch Consolidate is to support mature projects, such as those that have been selected in such a way that they can take the step from the laboratory to the market and society, creating new research-based companies or solutions and thus improving health and quality of life. of people.

This year selected participants in a project by the University of Rovira y Virgili (URV) in a consortium with researchers from the Institute for Sanitary Research Pere Virgili (IISPV) to create new medical devices that improve the monitoring of electrical brain signals in newborns and adults; one of Bosch and Gimper Foundationfrom the University of Barcelona, ​​in a consortium with researchers from the University of Granada and the University of Catania to develop new drugs that reduce pain, and one from the German Research Institute Trias i Pujol (IGTP), which is developing a new immunotherapy based on monoclonal antibodies for the treatment of cancer.

These projects will receive financial assistance of 300,000 euros each for its development in the next two years. Assistance will be directed to areas such as the technological development of an asset, research for regulatory approval, staff recruitment or intellectual property management, among others.

In addition, its researchers will receive one-on-one mentoring support and will have other support activities such as expert advice in determining their development and commercialization plans.

Since 2015, the La Caixa Foundation has given 18 million euros for 173 innovative projects among CaixaResearch Validate calls, for earlier innovation, and CaixaResearch Consolidate. The projects have attracted additional investments of more than 10 million euros and 29 derivative companies have been created (spin off).